Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
ID: 336765Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336765

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-031.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for the "Drug Discovery for Nervous System Disorders" through the R01 Research Project Grant mechanism. This initiative aims to support the discovery of novel compounds for the prevention and treatment of nervous system disorders, emphasizing innovative approaches in the identification, design, synthesis, and preclinical testing of therapeutic candidates. The funding is particularly relevant for advancing therapies related to mental health, substance use, and aging, with a focus on high-impact research; however, clinical trials are not permitted under this announcement. Interested applicants must submit their proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. The funding period may extend up to five years, with no specified budget limits.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-031-Full-Announcement.html
    PAR-22-031.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) focusing on "Drug Discovery for Nervous System Disorders" via the R01 Research Project Grant mechanism. This initiative seeks to advance the discovery of novel compounds for treating mental and nervous system disorders, specifically through the identification, design, synthesis, and testing of therapeutic candidates. Emphasis is placed on innovative approaches and the potential for high-impact research, particularly targeting conditions related to substance use, alcohol use, and aging. Key submission deadlines are outlined, with applications accepted from eligible organizations including higher education institutions and non-profits. The funding aims not only to accelerate drug discovery but also to enhance scientific knowledge and methodologies in therapeutic development. Importantly, clinical trials are not permitted under this FOA. Applicants are encouraged to contact NIH representatives for guidance and must ensure compliance with stringent submission requirements. The project funding period can extend up to five years with no specified budget limits. This FOA targets the development of therapies based on recent scientific advancements in neuroscience, linking them to the pressing need for innovative treatments in mental health and aging-related conditions.
    Similar Opportunities
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Blueprint Neurotherapeutics Network (BPN) for small molecule drug discovery and development targeting disorders of the nervous system. This initiative invites applications for cooperative agreements (UG3/UH3) from neuroscience investigators to advance their projects through various stages of drug development, including Discovery and Development phases, while collaborating with NIH-funded consultants and specialized contract research organizations (CROs). The program emphasizes the importance of innovative approaches to treating complex neurological conditions and requires adherence to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by August 18, 2026.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.